Lilly trial data show retatrutide cut body weight about 30% over 80 weeks
UCHealth endocrinologist Cecilia Low Wang says the triple agonist also reduced knee arthritis pain by up to 73% and sleep apnea events by roughly 60%.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 16 03:00 ETSource: UCHealth
The wire
- 01Manufacturer data presented at the American Diabetes Association meeting in New Orleans showed volunteers on retatrutide lost an average of 70.3 pounds over about 80 weeks, with more than 45% losing over 30% of body weight.
- 02Participants with BMI above 35 lost about 85 pounds, or 30.3% of body weight, after roughly two years, a range the UCHealth expert says matches or exceeds bariatric surgery outcomes.
- 03The findings have not been peer reviewed, the FDA has not approved retatrutide, and the drug is unlikely to reach patients before 2027 at the earliest.
From the source
Read at uchealth.orgRetatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery
Retatrutide, the newest type of weight-loss drug, helped people lose an average of 70 pounds or about 30% of their body weight over 80 weeks, according to study data from the drug’s manufacturer .